Clinical Trial Update: Phase I/II Comparison of Efficacy and Safety of BIBF 1120 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

Phase II trial comparing BIBF 1120 (nintedanib) to sorafenib in advanced hepatocellular carcinoma to assess efficacy and safety; results were posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• BIBF 1120 (nintedanib)
• Sorafenib (Sorafenib)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Carcinoma, Hepatocellular | Phase 2 | Status: COMPLETED | Results posted: 2015-08-07